
Pharvaris B.V. (PHVS) Stock Forecast & Price Target
Pharvaris B.V. (PHVS) Analyst Ratings
Bulls say
Pharvaris is supported by compelling Phase 3 CHAPTER-3 data showing once-daily oral deucrictibant reduced monthly HAE attacks by 83% overall and 87% in Type 1/2 patients, with rapid onset, 46% of patients attack-free, and no treatment-related serious adverse events. That profile appears “injectable-like” while preserving oral convenience, a meaningful differentiation in a competitive HAE market where physician survey data suggest substantial willingness to switch from both oral and injectable therapies. The outlook is further reinforced by a clean balance sheet with $363M in cash at the end of 2Q26 providing runway into 2028, open-label extension enrollment by 80 of 83 eligible patients, and multiple near-term catalysts including an April 23, 2027 PDUFA and an NDA submission in 1H27.
Bears say
Pharvaris is a high-risk, development-stage biopharmaceutical company whose value depends heavily on deucrictibant succeeding in regulatory review and ultimately proving safe and effective, while failure of IR or XR, unexpected safety signals, or slow market uptake would materially weaken the investment case. The HAE market is increasingly crowded, which raises the bar for share capture and makes any label limitations, competitive updates, or weaker-than-expected differentiation especially damaging to future commercialization prospects. Financially, the company remains non-revenue-generating and will likely need access to capital markets to fund development and commercialization, so any inability to raise adequate funds could constrain its pipeline and amplify stock volatility.
This aggregate rating is based on analysts' research of Pharvaris B.V. and is not a guaranteed prediction by Public.com or investment advice.
Pharvaris B.V. (PHVS) Analyst Forecast & Price Prediction
Start investing in Pharvaris B.V. (PHVS)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Pharvaris B.V. (PHVS) Forecast
Pharvaris B.V. (PHVS) Analyst Forecast & Price Prediction
Start investing in Pharvaris B.V. (PHVS)
Order type
Buy in
Order amount
Est. shares
0 shares